Details

Autor(en) / Beteiligte

• Pönisch, Wolfram
• Moll, Barbara
• Bourgeois, Malvina
• Andrea, Marc
• Schliwa, Thomas
• Heyn, Simone
• Schmalfeld, Marion
• Edelmann, Thomas
• Becker, Cornelia
• Hoffmann, Franz Albert
• Schwarzer, Andreas
• Kreibich, Ute
• Egert, Matthias
• Stiegler, Runa
• Krahl, Rainer
• Remane, Yvonne
• Bachmann, Anette
• Lindner, Tom
• Weidhase, Lorenz
• Petros, Sirak
• Fricke, Stefan
• Vucinic, Vladan
• Al Ali, Haifa
• Niederwieser, Dietger

Titel

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure

Ist Teil von

• Journal of cancer research and clinical oncology, 2013-11, Vol.139 (11), p.1937-1946

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2013

Quelle

2022 ECC(Springer)

Beschreibungen/Notizen

• Introduction Serious renal failure represents a severe complication of multiple myeloma (MM), with an estimated 25–50 % of patients being affected. Both bortezomib and bendamustine have been identified as quickly acting, effective and well-tolerated drugs and might therefore constitute an adequate combination regimen for patients presenting with light chain-induced renal failure. Methods Between March 2005 and March 2013, 36 patients with relapsed/refractory MM and light chain-induced renal failure (creatinine clearance <60 ml/min) were treated with bendamustine 60 mg/m 2 on days 1 and 2, bortezomib 1.3 mg/m 2 on days 1, 4, 8 and 11 and prednisone 100 mg on days 1, 2, 4, 8 and 11 (BPV). Patients were divided according to severity of renal impairment into group A ( n  = 20) with moderate or severe renal dysfunction (eGFR 15–59 ml/min) and group B ( n  = 16) with renal failure/dialysis (eGFR <15 ml/min). Results Twenty-four patients (67 %) responded with three CR, three nCR, six VGPR and 12 PR. Six patients had minor response, two stable and four progressive disease. With a median follow-up period of 22 months, median progression-free survival (PFS) and overall survival (OS) for patients of group A were 10 and 25 months, respectively. This outcome was significantly better compared to patients of group B with a median PFS and OS of 3 and 7 months, respectively. Eleven patients showed a CRrenal, five a PRrenal and 15 a MRrenal. Summary These results indicate that this BPV combination is feasible, effective and well tolerated in patients with relapsed/refractory MM and light chain-induced renal failure.